Carmichael is the founding partner of Material Impact, a fund that seeks out transformative technologies and builds them into enduring companies that solve real-world problems. The fund's strategy is based on Carmichael’s successful career as an entrepreneur-investor in “materials,” blending a unique business model of licensing university technology and commercializing it through targeted partnerships with Fortune 500 companies. Existing portfolio companies include Soft Robotics, Zero Mass Water, and Amastan Technologies. As a General Partner at North Bridge Venture Partners, Carmichael financed and built several successful companies from the ground up, including 1366 technologies, Foro Energy, and MC10. As co-founder and chairman of the nonprofit Diagnostics For All, he is developing paper-based diagnostics to serve marginalized patients globally. Prior to North Bridge, Carmichael co-founded several ventures, and served as President and CEO of Arsenal Medical. Prior to his entrepreneurial career, Carmichael worked in business development at GelTex Pharmaceuticals, acquired by Genzyme for $1.3 billion, and in new product and business development at Dow Chemical (formerly Union Carbide Corporation). Carmichael serves on the boards for the National Venture Capital Association and Massachusetts General Hospital Physician Organization. In 1999, he was named by MIT’s Technology Review as one of the world’s top 100 young entrepreneurs. Carmichael is a trustee of Duke University. Carmichael received his BS and PhD in organic chemistry from Duke University and completed his postdoctoral National Science Foundation fellowship at Harvard University. Carmichael also has an MBA from MIT Sloan School of Management.